Reuters logo
BRIEF-Innate Pharma reports first clinical data for monalizumab
November 30, 2016 / 9:41 AM / a year ago

BRIEF-Innate Pharma reports first clinical data for monalizumab

Nov 30 (Reuters) - Innate Pharma SA :

* First clinical data for monalizumab as a single agent in cancer patients show favorable safety profile

* Data from dose-ranging part of a phase I/II trial of monalizumab in 18 patients with advanced gynecologic malignancies

* Monalizumab had no dose-limiting toxicities, highest dose level chosen for cohort expansion part

* Expansion cohort in four indications of gynecologic malignancies is ongoing

* Preliminary efficacy data showed short-term disease stabilization in 41 pct of patients, including one patient with a mixed response

* Cohort expansion part of this trial (up to 98 patients) is ongoing at recommended phase II dose (10 mg/kg) in patients with platinum sensitive ovarian cancer, platinum-resistant ovarian cancer, epithelial endometrial cancer and squamous cell carcinoma of cervix Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below